Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.

Journal of the American College of Cardiology(2023)

Cited 9|Views23
No score
Abstract
The primary and secondary endpoints of the trial were negative. Positive signals in prespecified, and post hoc exploratory analyses suggest MPCs may improve outcomes, especially in patients with inflammation.
More
Translated text
Key words
cell therapy,heart failure with reduced ejection fraction,major adverse cardiovascular events,mesenchymal precursor cells
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined